Bioanalyticial Systems Logo
US09058M1036

Bioanalyticial Systems

Ins Portfolio
Über 2000 Dividenden-Werte in einem kostengünstigen ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

 Anzeige

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +5,34(+206,90%). Der Median liegt bei +5,34(+206,90%).

Kaufen
  2
Halten
  1
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

  • Foto von Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript

    Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript

    Call Start: 16:30 January 1, 0000 5:20 PM ET Inotiv, Inc. (NASDAQ:NOTV ) Q2 2025 Earnings Conference Call May 7, 2025, 04:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer John Sagartz - Chief Strategy Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Nelson Cox - Lake Street Capital Markets Dave Windley - Jefferies Operator Good day, everyone, and welcome to today's Inotiv Second Quarter Fiscal 2025 Earnings Call. [Operator Instructions] Please note, today's call will be recorded and I will be standing by should you need any assistance.» Mehr auf seekingalpha.com

  • Foto von Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates

    Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates

    Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.29 per share a year ago.» Mehr auf zacks.com

  • Foto von Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update

    Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update

    —  Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million—  Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million—  Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q2 FY 2025”) ended March 31, 2025 and six months ("YTD FY 2025") ended March 31, 2025.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Bioanalyticial Systems einen Umsatz von +115,20 Mio und ein Nettoeinkommen von 26,55 Mio
(EUR)Dez. 2024
YOY
Umsatz+115,20 Mio6,01%
Bruttoeinkommen+24,06 Mio38,37%
Nettoeinkommen26,55 Mio90,75%
EBITDA1,72 Mio122,55%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+59,06 Mio
Anzahl Aktien
33,87 Mio
52 Wochen-Hoch/Tief
+5,76 - +1,02
DividendenNein
Beta
4,06
KGV (PE Ratio)
0,44
KGWV (PEG Ratio)
0,00
KBV (PB Ratio)
+0,31
KUV (PS Ratio)
+0,14

Unternehmensprofil

Name
Bioanalyticial Systems
CEO
Robert W. Leasure Jr.
SitzWest Lafayette, in
USA
Mitarbeiter1.977

Ticker Symbole

BörseSymbol
NASDAQ
NOTV
🍪

Parqet nutzt Cookies.Erfahre Mehr